Skip to main content
Top
Published in: BMC Cancer 1/2020

01-12-2020 | Thyroidectomy | Research article

Clinical characteristics and prognostic factors of Hurthle cell carcinoma: a population based study

Authors: Xingtong Zhou, Zhibo Zheng, Chuyan Chen, Bangbo Zhao, Hongtao Cao, Tianhao Li, Xudong Liu, Weibin Wang, Yongning Li

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Thyroid Hurthle cell carcinoma (HCC) is a rare disease with high risk of invasion and metastasis and poor prognosis. The clinical characteristics, prognosis and treatment of HCC are still controversial, and clinical data are still limited to some case reports. Therefore, understanding the characteristics and survival factors of HCC is clinically necessary.

Methods

This study collected data from HCC patients diagnosed pathologically from 2004 to 2015, including basic population characteristics, tumor characteristics, and epidemiological and survival data. The data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database to conduct a population cohort study.

Results

A total of 2101 HCC patients with an average age of 55.42 ± 15.27 years were enrolled in this study. Of them, 1740 (82.82%) patients had local disease, 245 (11.66%) had regional disease, and 89 (4.24%) had distant disease. Total thyroidectomy was performed in 1669 (79.44%) patients, partial thyroidectomy was performed in 382 (18.18%) patients, and radioactive iodine (RAI) was used in 1155 (54.97%) patients. The 5-year and 10-year cancer-specific survival rate was 95.4 and 92.6%, respectively. The distant disease group had significantly more male patients, multifocal tumors, and extensive tumors compared to the local disease group. Multivariate survival analysis showed that age (P < 0.05), SEER stage (P < 0.001), and T-stage (P = 0.001) had significant effects on survival. There was no significant difference in survival between total and partial thyroidectomy (P = 0.078), or between RAI and non-RAI (P = 0.733).

Conclusion

Male gender, multifocal tumors, and extended tumors are associated with increased risk of late stage HCC. Age over 45 years, distant SEER stage, and late T-stage are independent risk factors for mortality in HCC.
Literature
1.
go back to reference Johnson TL, et al. Hurthle cell thyroid tumors. An immunohistochemical study. Cancer. 1987;59(1):107–12.PubMedCrossRef Johnson TL, et al. Hurthle cell thyroid tumors. An immunohistochemical study. Cancer. 1987;59(1):107–12.PubMedCrossRef
3.
go back to reference Sheffield, E.A., Armed forces institute of pathology, atlas of tumor pathology: 3rd Series. Tumors of the thyroid gland. J. Rosai, M. L. Carcangiu and R. A. DeLellis. Armed Forces Institute of Pathology, Washington, DC, 1992. No. of pages: 343. Price: $58. ISBN: 1 881041 03 4. The Journal of Pathology, 1993 171(3): p. 247–248. Sheffield, E.A., Armed forces institute of pathology, atlas of tumor pathology: 3rd Series. Tumors of the thyroid gland. J. Rosai, M. L. Carcangiu and R. A. DeLellis. Armed Forces Institute of Pathology, Washington, DC, 1992. No. of pages: 343. Price: $58. ISBN: 1 881041 03 4. The Journal of Pathology, 1993 171(3): p. 247–248.
5.
go back to reference Bishop JA, et al. Histological patterns of locoregional recurrence in Hurthle cell carcinoma of the thyroid gland. Thyroid. 2012;22(7):690–4.PubMedCrossRef Bishop JA, et al. Histological patterns of locoregional recurrence in Hurthle cell carcinoma of the thyroid gland. Thyroid. 2012;22(7):690–4.PubMedCrossRef
6.
go back to reference Jr, Y.J., et al., SEER Summary Staging Manual −2000: Codes and Coding Instructions, National Cancer Institute, NIH Pub. No. 01–4969, Bethesda, MD, 2001., 2001. Jr, Y.J., et al., SEER Summary Staging Manual −2000: Codes and Coding Instructions, National Cancer Institute, NIH Pub. No. 01–4969, Bethesda, MD, 2001., 2001.
7.
go back to reference Ghossein RA, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. 2006;106(8):1669–76.PubMedCrossRef Ghossein RA, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. 2006;106(8):1669–76.PubMedCrossRef
8.
go back to reference Stojadinovic A, et al. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001;19(10):2616–25.PubMedCrossRef Stojadinovic A, et al. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001;19(10):2616–25.PubMedCrossRef
9.
go back to reference Nagar S, et al. Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery. 2013;154(6):1263–71 discussion 1271.PubMedCrossRef Nagar S, et al. Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery. 2013;154(6):1263–71 discussion 1271.PubMedCrossRef
10.
go back to reference Kuo EJ, Roman SA, Sosa JA. Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery. 2013;154(6):1246–53 discussion 1253-4.PubMedCrossRef Kuo EJ, Roman SA, Sosa JA. Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery. 2013;154(6):1246–53 discussion 1253-4.PubMedCrossRef
11.
go back to reference Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013;119(3):504–11.PubMedCrossRef Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013;119(3):504–11.PubMedCrossRef
12.
go back to reference McHenry CR, Sandoval BA. Management of follicular and Hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am. 1998;7(4):893–910.PubMedCrossRef McHenry CR, Sandoval BA. Management of follicular and Hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am. 1998;7(4):893–910.PubMedCrossRef
13.
go back to reference Besic N, et al. The role of radioactive iodine in the treatment of Hurthle cell carcinoma of the thyroid. Thyroid. 2003;13(6):577–84.PubMedCrossRef Besic N, et al. The role of radioactive iodine in the treatment of Hurthle cell carcinoma of the thyroid. Thyroid. 2003;13(6):577–84.PubMedCrossRef
14.
go back to reference Carcangiu ML, et al. Follicular Hurthle cell tumors of the thyroid gland. Cancer. 1991;68(9):1944–53.PubMedCrossRef Carcangiu ML, et al. Follicular Hurthle cell tumors of the thyroid gland. Cancer. 1991;68(9):1944–53.PubMedCrossRef
15.
go back to reference Kushchayeva Y, et al. Prognostic indications for Hurthle cell cancer. World J Surg. 2004;28(12):1266–70.PubMedCrossRef Kushchayeva Y, et al. Prognostic indications for Hurthle cell cancer. World J Surg. 2004;28(12):1266–70.PubMedCrossRef
16.
go back to reference Lopez-Penabad L, et al. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer. 2003;97(5):1186–94.PubMedCrossRef Lopez-Penabad L, et al. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer. 2003;97(5):1186–94.PubMedCrossRef
17.
go back to reference Bhattacharyya N. Survival and prognosis in Hurthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003;129(2):207–10.PubMedCrossRef Bhattacharyya N. Survival and prognosis in Hurthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003;129(2):207–10.PubMedCrossRef
Metadata
Title
Clinical characteristics and prognostic factors of Hurthle cell carcinoma: a population based study
Authors
Xingtong Zhou
Zhibo Zheng
Chuyan Chen
Bangbo Zhao
Hongtao Cao
Tianhao Li
Xudong Liu
Weibin Wang
Yongning Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-06915-0

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine